Broad-Spectrum Antivirals, Built on Host Biology
LuAnce combines mitochondrial and immune biology with focused development, regulatory execution and global partnering to advance next-generation antiviral programs.
A focused antiviral R&D and development company
LuAnce Co., Ltd. (주식회사 루앤스) is a Korean biotechnology company developing host-directed antiviral and Long COVID therapeutics grounded in mitochondrial and innate-immune biology, with GMP drug-substance manufacturing.